Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Incannex Healthcare Limited Common Stock

IXHL

Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.

Last trade $1.72
Day change -$0.21 (-10.88%)
Day range $1.71 – $1.97
Volume 139,707
Market cap $24M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for IXHL.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for IXHL.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.

GlobeNewswire Inc.

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.

GlobeNewswire Inc.

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Healthcare announced first patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral fixed-dose combination candidate for treating obstructive sleep apnea. The milestone follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The DReAMzz study aims to optimize dose selection and strengthen the clinical foundation for planned Phase 3 development.

GlobeNewswire Inc.

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Healthcare received A$6.0 million in R&D tax incentive refunds from the Australian Government with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million in non-dilutive capital. The company plans to use these proceeds to advance clinical programs including IHL-42X and PSX-001, while maintaining its share repurchase program and strengthening its debt-free balance sheet.

GlobeNewswire Inc.

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare Inc. (Nasdaq: IXHL) has been recognized as the winner of the 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards for its lead drug candidate IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea. The Phase 2 RePOSA trial demonstrated statistically significant improvements in key endpoints including reductions in apnea-hypopnea index, improved oxygenation, sleep quality, and daytime fatigue.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 27, 20261-for-30reverse split